HC Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

HC Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-7,450	Closed	-$921K	–	101
2020 Q4	$921K	Sell	7,450 -124	-2%	-$16.3K	0.63%	26
2020 Q3	$738K	Sell	7,574 -504	-6%	-$63K	0.6%	28
2020 Q2	$1.26M	Buy	+8,078	New	+$1.23M	1.04%	24

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

HC Advisors's RETA Position: Q1 2021 in Review

HC Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2021, closing a stake of 7,450 shares — an estimated $921K sold.

HC Advisors first reported a position in RETA in Q2 2020 and held it in 3 quarters. The position peaked at $1.26M in Q2 2020. 201 funds tracked by Wall St. Rank hold RETA as of Q1 2021.

HC Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2021 after selling out during the quarter.
HC Advisors sold 7,450 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2021, an estimated $921K.
HC Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2020 and held it in 3 quarters.
HC Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.26M in Q2 2020.
201 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2021.

Based on HC Advisors's 13F filing for Q1 2021, filed 7 May 2021.